Short Interest in Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Declines By 38.2%

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) was the recipient of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totaling 9,400 shares, a decrease of 38.2% from the August 31st total of 15,200 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ∞ days. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ∞ days.

Analyst Ratings Changes

Separately, Zacks Research upgraded Basilea Pharmaceutica to a “hold” rating in a research report on Wednesday, September 24th. One analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company presently has an average rating of “Hold”.

Basilea Pharmaceutica Stock Performance

Shares of Basilea Pharmaceutica stock opened at $67.75 on Tuesday. The firm has a 50-day simple moving average of $67.62 and a two-hundred day simple moving average of $58.60. Basilea Pharmaceutica has a fifty-two week low of $47.50 and a fifty-two week high of $67.75.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.